Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates

分组1 - Royalty Pharma reported quarterly earnings of $1.17 per share, exceeding the Zacks Consensus Estimate of $1.11 per share, and showing an increase from $1.04 per share a year ago, resulting in an earnings surprise of +5.41% [1][2] - The company achieved revenues of $814 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.34%, and up from $735 million in the same quarter last year [2] - Royalty Pharma has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2][3] 分组2 - The stock has gained approximately 48.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.1% [3] - The future performance of Royalty Pharma's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.34 on revenues of $784.56 million, and for the current fiscal year, it is $4.52 on revenues of $3.16 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Royalty Pharma belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]